Meriofert Pfs

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to treat infertility due to anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Pfs is a gonadotropin used in fertility treatment protocols that require stimulation of ovarian function. - Infertility due to anovulation: induces follicular development and ovulation to improve chances of conception. - Assisted reproductive technology cycles: provides controlled ovarian stimulation for in‑vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). - Ovarian stimulation for intrauterine insemination: enhances follicle growth to increase the likelihood of successful insemination.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal bloating or discomfort: transient gastrointestinal symptoms. - Nausea or mild headache: occasional systemic reactions. - Mild ovarian hyperstimulation syndrome (OHSS): mild ovarian enlargement with fluid shift. - Hot flashes or mild flushing: transient vasomotor symptoms.

Serious or Rare Side Effects: - Severe OHSS: marked ovarian enlargement, ascites, thromboembolic risk. - Allergic reaction or anaphylaxis: rash, swelling, respiratory distress. - Multiple pregnancy: increased risk of twins or higher-order gestations. - Ectopic pregnancy: implantation outside the uterine cavity. - Severe abdominal pain: may indicate ovarian torsion or rupture.

Meriofert Pfs should be used under close medical supervision with regular monitoring of ovarian response. - Monitor ovarian response: adjust dosing based on ultrasound and estradiol levels. - Assess risk of OHSS: evaluate patient history and limit stimulation in high‑risk individuals. - Avoid use in uncontrolled thyroid disease: correct thyroid function before initiation. - Caution in patients with thromboembolic disorders: monitor for clotting complications. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Pfs may interact with other agents that affect ovarian stimulation or coagulation. Major Interactions (Avoid): - GnRH agonists: may potentiate response, increasing OHSS risk. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - Concurrent gonadotropins: additive effect can lead to excessive stimulation. Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may alter drug response, require dose adjustment. - Corticosteroids: can affect follicular development, monitor outcomes. - Anticoagulants: monitor for thrombotic events if severe OHSS occurs.